From 954d17fac2ff84f9115d7c76ab73b7ff267e81f5 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 22 Mar 2026 04:15:38 +0000 Subject: [PATCH 1/3] extract: 2026-03-22-arise-state-of-clinical-ai-2026 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...of US physicians daily within two years.md | 6 ++++ ...iagnostic accuracy in randomized trials.md | 6 ++++ ...03-22-arise-state-of-clinical-ai-2026.json | 34 +++++++++++++++++++ ...6-03-22-arise-state-of-clinical-ai-2026.md | 16 ++++++++- 4 files changed, 61 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-03-22-arise-state-of-clinical-ai-2026.json diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 35246dfc4..9334c8dcc 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -36,6 +36,12 @@ OpenEvidence reached 1 million clinical consultations in a single 24-hour period OpenEvidence reached 30M+ monthly consultations by March 2026, including a historic milestone of 1 million consultations in a single day on March 10, 2026. The company projects 'more than 100 million Americans will be treated by a clinician using OpenEvidence this year.' This represents continued exponential growth from the 18M monthly consultations reported in December 2025. +### Additional Evidence (challenge) +*Source: [[2026-03-22-arise-state-of-clinical-ai-2026]] | Added: 2026-03-22* + +ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rather than validation of clinical value. Clinicians use OE to 'bypass slow internal IT systems' because institutional tools are too slow for clinical workflows. This suggests rapid adoption reflects institutional system failure, not OE's clinical superiority. + + Relevant Notes: - [[centaur team performance depends on role complementarity not mere human-AI combination]] -- OpenEvidence is the clinical centaur: AI provides evidence synthesis, physician provides judgment diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index 0599d652c..6c4e105c9 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -30,6 +30,12 @@ OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed OpenEvidence's medRxiv preprint (November 2025) showed 24% accuracy for relevant answers on complex open-ended clinical scenarios, despite achieving 100% on USMLE-type multiple choice questions. This 76-percentage-point gap between benchmark performance and open-ended clinical scenarios confirms that structured test performance does not predict real-world clinical utility. +### Additional Evidence (extend) +*Source: [[2026-03-22-arise-state-of-clinical-ai-2026]] | Added: 2026-03-22* + +ARISE report identifies specific failure modes: real-world performance 'breaks down when systems must manage uncertainty, incomplete information, or multi-step workflows.' This provides mechanistic detail for why benchmark performance doesn't translate — benchmarks test pattern recognition on complete data while clinical care requires uncertainty management. + + Relevant Notes: - [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] -- Stanford/Harvard study shows physician overrides degrade AI performance from 90% to 68% diff --git a/inbox/queue/.extraction-debug/2026-03-22-arise-state-of-clinical-ai-2026.json b/inbox/queue/.extraction-debug/2026-03-22-arise-state-of-clinical-ai-2026.json new file mode 100644 index 000000000..4de2b3cb4 --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-22-arise-state-of-clinical-ai-2026.json @@ -0,0 +1,34 @@ +{ + "rejected_claims": [ + { + "filename": "clinical-ai-safety-paradox-drives-shadow-it-adoption-because-institutional-tools-are-too-slow.md", + "issues": [ + "missing_attribution_extractor", + "opsec_internal_deal_terms" + ] + }, + { + "filename": "clinical-ai-real-world-performance-breaks-down-under-uncertainty-and-incomplete-information.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "clinical-ai-safety-paradox-drives-shadow-it-adoption-because-institutional-tools-are-too-slow.md:set_created:2026-03-22", + "clinical-ai-real-world-performance-breaks-down-under-uncertainty-and-incomplete-information.md:set_created:2026-03-22" + ], + "rejections": [ + "clinical-ai-safety-paradox-drives-shadow-it-adoption-because-institutional-tools-are-too-slow.md:missing_attribution_extractor", + "clinical-ai-safety-paradox-drives-shadow-it-adoption-because-institutional-tools-are-too-slow.md:opsec_internal_deal_terms", + "clinical-ai-real-world-performance-breaks-down-under-uncertainty-and-incomplete-information.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-22" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md b/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md index 621138fc4..8547151b8 100644 --- a/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md +++ b/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md @@ -7,9 +7,13 @@ date: 2026-01-01 domain: health secondary_domains: [ai-alignment] format: report -status: unprocessed +status: enrichment priority: high tags: [clinical-ai, state-of-ai, stanford, harvard, arise, openevidence, safety-paradox, outcomes-evidence, real-world-performance] +processed_by: vida +processed_date: 2026-03-22 +enrichments_applied: ["medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -56,3 +60,13 @@ Additional coverage: Stanford Department of Medicine news release, BABL AI, Harv PRIMARY CONNECTION: "medical LLM benchmarks don't translate to clinical impact" (existing KB claim) WHY ARCHIVED: Provides the first systematic framework for understanding clinical AI real-world performance gaps, introduces the "safety paradox" framing for consumer AI workaround behavior EXTRACTION HINT: The "safety paradox" is a novel mechanism claim — extract it separately from the benchmark-gap finding. Both have evidence (OE adoption behavior, real-world performance breakdown) and are specific enough to be arguable. + + +## Key Facts +- ARISE Network is a Stanford-Harvard research collaboration +- State of Clinical AI Report 2026 was released in January 2026 +- Report authors: Peter Brodeur MD, Ethan Goh MD, Adam Rodman MD, Jonathan Chen MD PhD +- Report explicitly names OpenEvidence as case study of consumer-facing medical AI +- Report calls for 'evaluation frameworks that focus on outcomes rather than engagement alone' +- Harvard Science Review called the report 'Beyond the Hype: The First Real Audit of Clinical AI' in February 2026 +- Report received coverage from Stanford Department of Medicine, BABL AI, Harvard Science Review, and Stanford HAI -- 2.45.2 From 7f79391407d7db8d060697b95b0009450e3e8808 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 22 Mar 2026 04:17:16 +0000 Subject: [PATCH 2/3] pipeline: archive 1 source(s) post-merge Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...6-03-22-arise-state-of-clinical-ai-2026.md | 58 +++++++++++++++++++ 1 file changed, 58 insertions(+) create mode 100644 inbox/archive/health/2026-03-22-arise-state-of-clinical-ai-2026.md diff --git a/inbox/archive/health/2026-03-22-arise-state-of-clinical-ai-2026.md b/inbox/archive/health/2026-03-22-arise-state-of-clinical-ai-2026.md new file mode 100644 index 000000000..efb56cc32 --- /dev/null +++ b/inbox/archive/health/2026-03-22-arise-state-of-clinical-ai-2026.md @@ -0,0 +1,58 @@ +--- +type: source +title: "State of Clinical AI Report 2026 (ARISE Network, Stanford-Harvard)" +author: "ARISE Network — Peter Brodeur MD, Ethan Goh MD, Adam Rodman MD, Jonathan Chen MD PhD" +url: https://arise-ai.org/report +date: 2026-01-01 +domain: health +secondary_domains: [ai-alignment] +format: report +status: processed +priority: high +tags: [clinical-ai, state-of-ai, stanford, harvard, arise, openevidence, safety-paradox, outcomes-evidence, real-world-performance] +--- + +## Content + +The State of Clinical AI (2026) was released in January 2026 by the ARISE network, a Stanford-Harvard research collaboration. The inaugural report synthesizes evidence on clinical AI performance in real-world settings vs. controlled benchmarks. + +**Key findings:** + +**Benchmark vs. real-world gap:** +- LLMs demonstrate strong performance on diagnostic benchmarks and structured clinical cases +- Real-world performance "breaks down when systems must manage uncertainty, incomplete information, or multi-step workflows" — which describes everyday clinical care +- "Real-world care remains uneven" as an evidence base + +**The "Safety Paradox" (novel framing):** +- Clinicians turn to "nimble, consumer-facing medical search engines" (specifically citing OpenEvidence) to check drug interactions and summarize patient histories, "often bypassing slow internal IT systems" +- This represents a **safety paradox**: clinicians prioritize speed over compliance because institutional AI tools are too slow for clinical workflows +- OE adoption is explicitly characterized as **shadow-IT workaround behavior** that has become normalized + +**Evaluation framework:** +- The report argues current evaluation focuses on "engagement rather than outcomes" +- Calls for "clearer evidence, stronger escalation pathways, and evaluation frameworks that focus on outcomes rather than engagement alone" + +**OpenEvidence specifically named** as a case study of consumer-facing medical AI being used to bypass institutional oversight. + +Additional coverage: Stanford Department of Medicine news release, BABL AI, Harvard Science Review ("Beyond the Hype: The First Real Audit of Clinical AI," February 2026), Stanford HAI. + +## Agent Notes +**Why this matters:** The ARISE report is the first systematic, peer-network-authored overview of clinical AI's real-world state. Its framing of OE as "shadow IT" is significant — it recharacterizes OE's rapid adoption not as a sign of clinical value, but as clinicians working around institutional barriers. This frames the OE-Sutter Epic integration as moving from "shadow IT" to "officially sanctioned shadow IT" — the speed that made OE attractive is now institutionally embedded without resolving the governance gap. + +**What surprised me:** The explicit naming of OpenEvidence as a case study in the safety paradox. This is the first time a Stanford-affiliated academic review has characterized OE adoption as a workaround behavior rather than evidence of clinical value. At $12B valuation and 30M+ consultations/month, this framing matters for how OE's safety profile is evaluated. + +**What I expected but didn't find:** Specific outcome data for any clinical AI tool. The report explicitly identifies this as the field's core gap — the absence of outcomes data is the finding, not an absence of coverage. + +**KB connections:** +- Directly extends Session 9 finding on the valuation-evidence asymmetry (OE at $12B, one retrospective 5-case study) +- The "safety paradox" framing provides vocabulary for why OE's governance gap is structural, not accidental +- Connects to the Sutter Health EHR integration (February 2026) — embedding OE in Epic formally addresses the speed problem while potentially entrenching the governance gap + +**Extraction hints:** Extract the "safety paradox" framing as a named mechanism: clinicians bypassing institutional AI governance to use consumer-facing tools because institutional tools are too slow. This is generalizable beyond OE. Secondary: extract the benchmark-vs-real-world gap finding as it applies to clinical AI at scale. + +**Context:** The ARISE network is the most credible academic voice on clinical AI evaluation practices. The report's release in January 2026 — coinciding with the NOHARM study findings — represents a coordinated moment of academic accountability for a rapidly scaling industry. The Harvard Science Review calling it "the first real audit" signals its significance in the field. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: "medical LLM benchmarks don't translate to clinical impact" (existing KB claim) +WHY ARCHIVED: Provides the first systematic framework for understanding clinical AI real-world performance gaps, introduces the "safety paradox" framing for consumer AI workaround behavior +EXTRACTION HINT: The "safety paradox" is a novel mechanism claim — extract it separately from the benchmark-gap finding. Both have evidence (OE adoption behavior, real-world performance breakdown) and are specific enough to be arguable. -- 2.45.2 From accb51f33c932734bea4660e587c31c1890c731a Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 22 Mar 2026 04:17:21 +0000 Subject: [PATCH 3/3] extract: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ... net cost impact inflationary through 2035.md | 6 ++++++ ...ealth-canada-rejects-dr-reddys-semaglutide.md | 16 +++++++++++++++- 2 files changed, 21 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 5b8a783b1..f0d0b2fdc 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -143,6 +143,12 @@ Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale. +### Additional Evidence (challenge) +*Source: [[2026-03-22-health-canada-rejects-dr-reddys-semaglutide]] | Added: 2026-03-22* + +Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff. + + Relevant Notes: diff --git a/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md b/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md index ad548a031..465b137ae 100644 --- a/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md +++ b/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md @@ -7,9 +7,13 @@ date: 2025-10-30 domain: health secondary_domains: [] format: news article -status: unprocessed +status: enrichment priority: high tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda] +processed_by: vida +processed_date: 2026-03-22 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -51,3 +55,13 @@ tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2. + + +## Key Facts +- Dr. Reddy's received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate in October 2025 +- Canada's semaglutide patents expired January 2026 +- Dr. Reddy's projected May 2026 Canada launch in its 87-country rollout plan +- Regulatory re-submission and review timeline: 8-12 months minimum +- Dr. Reddy's stated it is 'in constant touch with Canadian regulators' and has 'sent replies to their queries' +- The Canada launch is 'on pause' per company statement +- India launch of Obeda (generic semaglutide) confirmed March 21, 2026 -- 2.45.2